This volume offers a balanced and comprehensive snapshot of the changing landscape for vaccine markets.

The U.S. Supreme Court recieved an amicus brief on FDA regulation.

Murray Aitken, vice president of IMS Health, the world's largest source of drug-price and sales data, and MIT professor Ernst Berndt will explain why their research shows that average drug prices for seniors have declined, not increased, by more than 20 percent.

Congress enacted and renewed the Prescription Drug User Fee Acts (PDUFA) in 1992. The authors model and quantify the impact of PDUFA-I and -II on drug approval times.

Ernst R. Berndt and Anjli C. Warner discuss their new book, U.S. Markets for Vaccines: Characteristics, Case Studies, and Controversies.

This monograph argues that uniform pharmaceutical pricing legislation is bad public policy.

Studies of vaccines have suffered from a focus on pricing and access, missing the crucial question of how they are developed and brought to market.

When drug patents expire, cheap generic equivalents usually enter the market, drastically reducing prices and costs. Generic competition has arrived for many blockbuster drugs in the past few years, and much more is on the way. Sometimes, the manufacturer of a branded drug offers its own “authorized generic”...